Mumbai, Sept. 4 -- Cohance Lifesciences today announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio. Both the transactions will be funded through internal accruals.

Published by HT Digital Content Services with permission from Capital Market....